Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John W Marks

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Letters|March 6, 2012
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxinMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Biochemical Pharmacology|July 27, 2010
The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphomaMi-Ae Lyu, Bokyung Sung, Lawrence H Cheung, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 13, 2002
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumorsLiesbeth M Veenendaal, Hangqing Jin, Sophia Ran, et al.
Chemical Communications (Cambridge, England)|July 13, 2006
Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibodyJared M Ashcroft, Dmitri A Tsyboulski, Keith B Hartman, et al.
Neoplasia (New York, N.Y.)|May 11, 2010
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivoMi-Ae Lyu, Deepak Rai, Kwang Seok Ahn, et al.
Molecular Cancer Therapeutics|November 18, 2011
Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicityYu Cao, James D Marks, Qian Huang, et al.
Biochemical Pharmacology|June 13, 2012
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphomaMi-Ae Lyu, Lan V Pham, Bokyung Sung, et al.
The Journal of Investigative Dermatology|November 30, 2012
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentHong Zhou, Suhendan Ekmekcioglu, John W Marks, et al.
Journal of Virology|November 1, 2016
Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160Seth H Pincus, Kejing Song, Grace A Maresh, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Letters|March 6, 2012
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxinMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Biochemical Pharmacology|July 27, 2010
The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphomaMi-Ae Lyu, Bokyung Sung, Lawrence H Cheung, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 13, 2002
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumorsLiesbeth M Veenendaal, Hangqing Jin, Sophia Ran, et al.
Chemical Communications (Cambridge, England)|July 13, 2006
Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibodyJared M Ashcroft, Dmitri A Tsyboulski, Keith B Hartman, et al.
Neoplasia (New York, N.Y.)|May 11, 2010
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivoMi-Ae Lyu, Deepak Rai, Kwang Seok Ahn, et al.
Molecular Cancer Therapeutics|November 18, 2011
Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicityYu Cao, James D Marks, Qian Huang, et al.
Biochemical Pharmacology|June 13, 2012
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphomaMi-Ae Lyu, Lan V Pham, Bokyung Sung, et al.
The Journal of Investigative Dermatology|November 30, 2012
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentHong Zhou, Suhendan Ekmekcioglu, John W Marks, et al.
Journal of Virology|November 1, 2016
Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160Seth H Pincus, Kejing Song, Grace A Maresh, et al.
Pageof 2